Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peakWebcast scheduled for 7:00 PM ET / 4:00 PM PT
Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 StudyData Base Lock 2H January 2024Topline Data Readout Expected Early 1Q Calendar Year 2024Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC
HUB Cyber Security Ltd (NASDAQ:HUBC), a developer of Confidential Computing cybersecurity solutions and services ("HUB Security" or the "Company"), anticipates demonstrating strong success in the next two years. With